Home › Research › Biomarkers
Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges
Bolton CJ, Rostamzadeh A, Chin N, Fowler NR, Heidebrink J, Rahman-Fillipiak A, Romano RR, Clark LR et al.. The journal of prevention of Alzheimer's disease, 2025-07-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Blood-based biomarkers (BBMs) for Alzheimer's disease (AD) have advanced rapidly and may be a critical tool for broad community-based screening for AD and detection of AD pathology in individuals with cognitive impairment. To meet the impending demand for AD diagnosis, BBMs could be implemented in a primary care setting to maximize accessibility and efficiency. However, this primary care implementation would be associated with numerous challenges, including issues related to disclosure of test results to patients. In this perspective article, we highlight the need for and potential challenges of AD BBM results disclosure in a primary care setting. Drawing from existing studies of AD risk disclosure, we highlight key areas of consideration to maximize patient safety and comprehension of results. Resources are suggested to aid health systems in implementing BBM testing in primary care settings. Finally, we emphasize the need for further research on the accuracy of BBMs and the practice of disclosure in primary care settings.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bolton, C. J., Rostamzadeh, A., Chin, N., Fowler, N. R., Heidebrink, J., Rahman-Fillipiak, A., et al. (2025). Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100310
Vancouver
Bolton CJ, Rostamzadeh A, Chin N, Fowler NR, Heidebrink J, Rahman-Fillipiak A, et al. Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges. The journal of prevention of Alzheimer's disease. 2025. doi:10.1016/j.tjpad.2025.100310. PMID: 40713244.
BibTeX
@article{bolton2025-40713244,
author = {Bolton, C. J. and Rostamzadeh, A. and Chin, N. and Fowler, N. R. and Heidebrink, J. and Rahman-Fillipiak, A. and Romano, R. R. and Clark, L. R. and others},
title = {{Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2025},
doi = {10.1016/j.tjpad.2025.100310},
pmid = {40713244},
url = {https://doi.org/10.1016/j.tjpad.2025.100310}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, this primary care implementation would be associated with numerous challenges, including issues related to disclosure of test results to patients.
- In this perspective article, we highlight the need for and potential challenges of AD BBM results disclosure in a primary care setting.
- Drawing from existing studies of AD risk disclosure, we highlight key areas of consideration to maximize patient safety and comprehension of results.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 26 of the 58 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40713244) |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 26 of the 58 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.